Splash Beverage Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SBEV research report →
Range $0.5 – $5
Price Chart
About the company
Based in Fort Lauderdale, Florida, Splash Beverage Group, Inc. operates within the U. S.
- CEO
- Brady Cobb
- IPO
- 2019
- Employees
- 2
- HQ
- Fort Lauderdale, FL, US
Get TickerSpark's AI analysis on SBEV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
Latest fiscal year · YoY change
- Revenue
- $73.07K-98.2%
- Gross Profit
- $16.90K-95.2%
- Op Income
- $-14,186,220
- Net Income
- $-25,234,834-6.2%
- EPS
- $-47.88+32.3%
- OCF Growth
- +40.2%
- FCF Growth
- +40.2%
- 52W High
- $13.40
- 52W Low
- $0.25
- 50D MA
- $0.47
- 200D MA
- $1.90
- Beta
- -1.07
- RSI (14)
- 39
- Avg Volume
- 8.39M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Splash reported modestly better profitability metrics in Q3 as gross margin expanded and expenses fell, but revenue remained pressured by liquidity-driven inventory constraints and management’s main focus stayed on financing and acquisitions.· November 25, 2024
- Net sales were $381,000 in Q3 2024, down slightly from Q2, as limited inventory from liquidity issues constrained sales.
- Gross margin improved to $981,000 in Q3, with gross margin percentage rising to 30% from 23% in Q2 and 11% in Q1.
- EBITDA loss improved to $1.7 million from a $2.2 million loss in Q2; net loss was $4.6 million, also better than the prior quarter and Q3 2023.
- The company said it has secured roughly $8 million in funding commitments since August and is pursuing additional institutional capital of $7 million to $12 million.
- Management highlighted distribution gains, the restart of Qplash, and pending M&A as key growth drivers, while emphasizing liquidity as the main risk.
Q3 2024 net sales were $381,000, down slightly from Q2 2024, when sales were a little over $1 million. Gross margin increased by $244,000 sequentially to $981,000, and gross margin percentage rose to 30% from 23% in Q2 2024 and 11% in Q1 2024. EBITDA was a loss of $1.7 million versus a loss of $2.2 million in Q2 2024, and net loss was $4.6 million, improving by $700,000 sequentially and by $1 million versus Q3 2023. Cash ended at $457,000, and inventory was flat versus the prior quarter. Forward-looking commentary centered on completing the current capital raise, with management saying commitments are roughly $8 million and that it is working with two institutions targeting between $7 million and $12 million; Project White Hot is expected to move the company to positive cash flow from operations and positive EBITDA on a run-rate basis by Q3 2025, excluding M&A. Management also said the pending energy drink acquisition could close in early January, though holidays and audit timing could push it slightly later, and Western Son could slip into Q1.
Robert Nistico framed the quarter as a liquidity repair story rather than a demand story, saying the business has been hurt for well over a year by timing of cash inflows. He emphasized that the company is actively working on financing, sourcing, and acquisitions rather than waiting, and he pointed to the energy drink market as especially attractive after recent industry transactions. His tone was urgent but confident, repeatedly saying the company is “extremely close” to solving liquidity and is excited about the pending deals.
Julius Ivancsits said Q3 performance was affected by limited inventory tied to liquidity challenges, with net sales of $381,000 and EBITDA loss narrowing to $1.7 million from $2.2 million in Q2. He highlighted gross margin improvement to $981,000, or 30%, helped by lower wine costs at Copa Di Vino and Qplash’s 59% gross margins, and noted OpEx fell $1 million sequentially due to expense controls, the removal of the TapouT license fee, and lower share-based compensation. He also said cash ended at $457,000, collections were solid, inventory was flat, and the company has commitments for roughly $8 million while continuing to work on capital structure and lower cost of capital.
Most of the Q&A focused on liquidity, missed timelines, and funding progress. Management said the company’s issues have been “100% related to liquidity,” that it has signed documents for the balance of the raise, and that the target has never been $12 million but rather $8 million to $10 million, with roughly $8 million in commitments currently. On Western Son, Bill Meissner said due diligence is complete and the deal is waiting on the debt/equity raise, which could slip into Q1, while Robert Nistico said the unnamed energy drink acquisition is still confidential for corporate reasons and that the name will remain undisclosed until later.
The positive case from the call is that margin and expense trends improved despite weak revenue, suggesting the business model can perform better once liquidity normalizes. Management also described meaningful distribution expansion, the restart of Qplash, and several retail wins, including Circle K authorization for Copa Di Vino and PLCB authorization for Chispo. The pending energy drink acquisition and Western Son LOI were presented as potentially transformative additions, with management saying the energy drink deal has top-line revenue above $30 million.
The main risk remains liquidity, which management said has directly limited inventory, sales, and transaction timing for more than a year. Revenue is still very small at $381,000, cash was only $457,000 at quarter end, and management acknowledged that funding and acquisitions may slip because of holiday timing and audit requirements. There is also an open legal issue related to ABG TapouT, and several key transactions remain conditional on completing financing.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 78.2%
- Shares Outstanding
- 6.30M
- Float Shares
- 8.58M
of shares held by institutions
16 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Summit Trail Advisors, LLC | 100.00K | 0 |
| Vanguard Group Inc | 11.09K | ▼ 4.98K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 8, 26 | Bondurant Michael Breen | other | 0 |
| Jun 8, 26 | Bondurant Michael Breen | other | 800,000 |
| Jun 8, 26 | Fore Thomas Butler | other | 500,000 |
| Jun 8, 26 | Caple Frederick William | other | 500,000 |
| Jun 8, 26 | Francis Knuettel II | other | 500,000 |
| Jun 8, 26 | Cobb Brady James | other | 925,000 |
| Jun 8, 26 | Scott Martin P | other | 700,000 |
| Apr 27, 26 | Francis Knuettel II | other | 0 |
| Feb 2, 26 | Cobb Brady James | other | 0 |
| Dec 15, 25 | Scott Martin P | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SBEV coverage
Recent articles, reports, and earnings notes.
No research on SBEV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SBEV report →Endovia Health Sciences Welcomes Historic Shift in Federal Cannabinoid Policy; Advances CannEpil® FDA Submission and Expands Development Pipeline
globenewswire.com · Aug 31
Endovia Health Sciences, formerly Splash Beverage, Achieves First FDA Regulatory Milestone for CannEpil® Veterinary Development Program
globenewswire.com · Aug 25
Splash Beverage Group to Become Endovia Health Sciences; New NYSE American Ticker “EDVA” Effective Monday
globenewswire.com · Aug 21
Splash Beverage Reports Second Quarter 2026 Results and Highlights Strategic Transformation Toward Endovia Health Sciences
globenewswire.com · Aug 20
Splash Beverage Group to Rebrand as Endovia Health Sciences
globenewswire.com · Aug 12
Splash Beverage Group Partners with Veteran Cannabinoid Drug-Development Team to Advance CannEpil® Through FDA Veterinary Pathway
globenewswire.com · Aug 5
Splash Beverage Group Expands CannEpil® Platform into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program
globenewswire.com · Jul 29
Splash Beverage Group Announces Significant Balance Sheet Improvement and Board Approval of Reverse Stock Split as Company Continues Strategic Transformation
globenewswire.com · Jul 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.